Benzinga · Aug 27, 2026
Piper Sandler Reiterates Overweight on Mesoblast, Raises Price Target to $39
Piper Sandler analyst Edward Tenthoff reiterates Mesoblast (NASDAQ:MESO) with a Overweight and raises the price target from $35 to $39.
ME
NASDAQ · MESO
Mesoblast Limited
Healthcare · Biotechnology
$15.48
Down-$0.02 (-0.13%)
Updated Sep 13, 2026, 11:17 PM
SID Score
4.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 2.36B
- P/E ratio
- -27.76
- Dividend yield
- 0.00%
- 52-week range
- $13.05 – $21.50
- Volume
- 180.17K
- Avg. volume
- 231.33K
Price performance
MESO price history
1M range · 19 trading sessions · Daily adjusted prices
MESO closed at $15.48 after 19 trading sessions, down 9.05% for the selected period.
- Last close
- $15.48
- Period change
- -9.05%
- Period low
- $15.48
- Period high
- $18.18
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | $15.57 | $15.65 | $15.425 | $15.48 | 180.17K |
| Sep 10, 2026 | $15.80 | $15.80 | $15.45 | $15.50 | 182.07K |
| Sep 9, 2026 | $16.25 | $16.25 | $15.965 | $16.14 | 200.02K |
| Sep 8, 2026 | $16.71 | $16.72 | $16.39 | $16.39 | 151.38K |
| Sep 4, 2026 | $17.04 | $17.335 | $17.03 | $17.32 | 93.5K |
| Sep 3, 2026 | $17.27 | $17.29 | $16.935 | $17.14 | 86.06K |
| Sep 2, 2026 | $16.98 | $17.40 | $16.98 | $17.29 | 296.63K |
| Sep 1, 2026 | $16.63 | $16.69 | $16.45 | $16.50 | 169.08K |
| Aug 31, 2026 | $16.92 | $16.95 | $16.63 | $16.76 | 173.73K |
| Aug 28, 2026 | $17.81 | $18.08 | $17.33 | $17.44 | 234.74K |
| Aug 27, 2026 | $17.82 | $18.33 | $17.3767 | $18.18 | 541.63K |
| Aug 26, 2026 | $17.08 | $17.08 | $16.67 | $16.84 | 108.42K |
| Aug 25, 2026 | $16.73 | $17.22 | $16.73 | $17.19 | 148.04K |
| Aug 24, 2026 | $16.80 | $16.80 | $16.44 | $16.64 | 177.71K |
| Aug 21, 2026 | $16.98 | $17.11 | $16.81 | $17.00 | 164.75K |
| Aug 20, 2026 | $17.70 | $17.97 | $17.41 | $17.43 | 273.59K |
| Aug 19, 2026 | $16.85 | $17.14 | $16.78 | $17.13 | 132.46K |
| Aug 18, 2026 | $16.91 | $17.06 | $16.60 | $16.67 | 182.26K |
| Aug 17, 2026 | $17.21 | $17.48 | $16.84 | $17.02 | 458.4K |
Latest MESO news
The latest Smart Investors Daily articles mentioning MESO.
Stock researchCompany · Overview
MESO research
Overview
Company profile and research snapshot.
Company profile
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $11.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 13, 2026 | PIPER SANDLER COMPANIES | Overweight | — |
| Jul 12, 2026 | CANTOR FITZGERALD | Overweight | — |
| Jul 9, 2026 | CANACCORD GENUITY | Buy | — |
| Jul 9, 2026 | JEFFERIES | Buy | — |
| Jun 30, 2026 | BELL POTTER SECURITIES | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 27, 2026
Mesoblast FY EPS $(0.04) Misses $0.01 Estimate, Sales $120.250M Beat $66.000M Estimate
Mesoblast (NASDAQ:MESO) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $0.01 by 500 percent. This is a 50 percent increase over losses of $(0.09) per share from the same
SeekingAlpha · Aug 27, 2026
Mesoblast Limited (MESO) Q4 2026 Earnings Call Transcript
Mesoblast Limited (MESO) Q4 2026 Earnings Call August 26, 2026 6:30 PM EDTCompany ParticipantsSilviu Itescu - Founder, CEO, MD, Chairman of Scientific...
Yahoo · Aug 27, 2026
Mesoblast Reports Substantial Revenue Growth to US$120M
RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment Financial Results and Operational Update for Full Year Ended June 30, 2026 NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended June 30, 2026 (FY2026). Chief Executive of Mesoblast Dr. Silviu Itescu, commented on the result: “We are very p
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
